Table of Contents

company-logo

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Dividend Announcement

• Adaptive Biotechnologies does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Adaptive Biotechnologies dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Adaptive Biotechnologies Dividend History

Adaptive Biotechnologies Dividend Yield

Adaptive Biotechnologies current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Adaptive Biotechnologies stock? Use our calculator to estimate your expected dividend yield:

Adaptive Biotechnologies Financial Ratios

P/E ratio-4.90
PEG ratio0.05
P/B ratio4.28
ROE-74.47%
Payout ratio0.00%
Current ratio3.52
Quick ratio3.38
Cash Ratio0.43

Adaptive Biotechnologies Dividend FAQ

Does Adaptive Biotechnologies stock pay dividends?
Adaptive Biotechnologies does not currently pay dividends to its shareholders.
Has Adaptive Biotechnologies ever paid a dividend?
No, Adaptive Biotechnologies has no a history of paying dividends to its shareholders. Adaptive Biotechnologies is not known for its dividend payments.
Why doesn't Adaptive Biotechnologies pay dividends?
There are several potential reasons why Adaptive Biotechnologies would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Adaptive Biotechnologies ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Adaptive Biotechnologies has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Adaptive Biotechnologies a dividend aristocrat?
Adaptive Biotechnologies is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Adaptive Biotechnologies a dividend king?
Adaptive Biotechnologies is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Adaptive Biotechnologies a dividend stock?
No, Adaptive Biotechnologies is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Adaptive Biotechnologies stocks?
To buy Adaptive Biotechnologies you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Adaptive Biotechnologies stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.